7 Best Revenue Growth Stocks to Buy According to Analysts

1. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Average Price Target Upside: 60.60%

5-Year Revenue CAGR: 34.29%

Number of Hedge Fund Holders: 55

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biopharmaceutical company dedicated to advancing therapies for rare genetic disorders, particularly those affecting the neuromuscular system like Duchenne muscular dystrophy (DMD).

It is focused on RNA-targeted therapeutics and gene therapies. The company utilizes a unique Precision Genetic Medicine Engine that integrates various cutting-edge approaches, including gene editing and RNA-based treatments. It has established itself as a leader in the field, with a portfolio of FDA-approved products that directly address specific genetic mutations associated with DMD.

Sarepta Therapeutics (NASDAQ:SRPT) has a consensus Strong Buy rating from 20 analysts and its average price target of $200.00 has a 60.60% upside to the stock’s price, as of September 27. It tops our list of the best revenue growth stocks to buy according to analysts.

In June, the company achieved a significant regulatory breakthrough by obtaining broad approval for ELEVIDYS, making it accessible to over 80% of patients in the U.S. with DMD. The traditional approval for all ambulant patients aged four and older, along with accelerated approval for non-ambulant patients, shows the urgency and impact of this therapy.

The ability to provide a treatment option to a large patient population shows its commitment to addressing critical unmet needs in the DMD community.

In the second quarter, 55 hedge funds tracked by Insider Monkey held positions in Sarepta Therapeutics (NASDAQ:SRPT) and their stakes amounted to $2.404 billion. As of June 30, VenBio Select Advisor is the most dominant shareholder in the company and has a position worth $474 million.

While we acknowledge the potential of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

Read Next: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.